|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Clinical response was predicted by tumor size (p = 0,002), lymph node metastasis (p = 0.007), distant metastasis (p = 0.001) and disease stage (p < 0.001), but TNFRSF1B A1466G genotype was independent of these factors.
|
20646319 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent findings highlight the importance of TNFR2 as a key regulator of activated natural FoxP3<sup>+</sup> regulatory T cells (Tregs) in inflammatory conditions, such as acute graft-vs.-host disease (GvHD) and the tumor microenvironment.
|
31555271 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TrkA and p75 showed no association with tumor grade, Fédération Internationale des Gynaecologistes et Obstetristes stage, chemotherapy status, the extent of residual disease, or survival (P > 0.05).
|
11705863 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We summarize the recent progress in understanding how TNFR2-dependent mechanisms promote carcinogenesis and tumor growth and discuss the potential value of TNFR2 in cancer treatment.
|
29892300 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Concentrations of tumor nuclear factor-receptor 2 (TNF-R2), e-selectin, and endostatin were significantly lower after consumption of the RP diet compared with WP (p < 0.05).
|
30685298 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that a certain level of expression of TNF-R75 is necessary for obtaining TNF-alpha-mediated tumor cell lysis in the absence of TNF-R75.
|
9685865 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These TNFR2 antibodies killed T<sub>regs</sub> isolated from ovarian cancer ascites more potently than it killed T<sub>regs</sub> from healthy donor samples, suggesting that these antibodies may have specificity for the tumor microenvironment.
|
28096513 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with the combination of TNFR2-blocking antibody and a CD25-targeted antibody also resulted in enhanced inhibition of tumor growth in a syngeneic 4T1 mouse model of breast cancer.
|
29295954 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TrkA and p75 were positively correlated and were respectively associated with the histoprognostic grading and the tumor type.
|
11389056 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.
|
19738070 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape.
|
30628200 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The interaction of tumor necrosis factor-α (TNF-α) with its receptors: TNFRSF1A and TNFRSF1B is critical for the promotion of tumor growth, invasion and metastasis.
|
25010932 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p75 neurotrophin receptor (p75(NTR)) functions as a tumor suppressor in prostate epithelial cells, where its expression declines with progression to malignant cancer.
|
18974393 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High expression and role of tumor necrosis factor receptor 2 (TNFR2) in cancer progression and prognosis has been reported in several types of tumors.
|
30127886 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In recent years, the role of TNFR2 has attracted much attention for its promotion role in several types of tumors.
|
29920311 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro and in vivo fluorescence imaging results suggest peptide P75 modified magnetosomes (Mag-P75) specifically bind to MDA-MB-468 and SKBR3 cells as well as xenograft tumors with surprisingly low accumulation in other organs including liver and kidney.
|
27888699 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, metastasis to the lung was observed in a few cases following development of mammary tumors in p75 CUX1 transgenic mice.
|
20224295 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, p75(NTR) protein was not detected in any tumor studied, unlike normal retina.
|
16555252 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p75 neurotrophin receptor (p75NTR) is a proximate cell membrane receptor glycoprotein that has been identified as a tumor and metastasis suppressor.
|
15342406 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In such animals, TNFR2-specific agonists inhibited tumor growth, enhanced tumor infiltration by CD8+ T cells and increased CD8+ T cell IFN-γ synthesis.
|
27626702 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, the role of the crosstalk between mTNF-α and TNFR2 in the tumor microenvironment will be discussed.
|
29234328 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed the following: i) TrkA and TrkB expression was significantly higher in AR-negative compared to AR-positive cells; ii) TrkA and TrkB expression was related to the invasive capacity/malignancy of PCa cells; iii) p75 NGFR could be considered a tumor suppressor gene which is present at high levels only in AR-positive cells; and iv) that NGF and BDNF (targeting TrkA/p75 NTR and TrKB, respectively) induced cell migration and this was inhibited by the CEP-701 treatment.
|
17143529 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Baseline burden T<sub>reg</sub>/T effector (T<sub>eff</sub>) ratios and the responsiveness of tumor and infiltrating T<sub>regs</sub> to TNFR2 antibody killing was studied.
|
30356161 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer.
|
29802567 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently, due to the distribution of TNFR2 and its pleiotropic effects, TNFR2 appears to be critical to keeping the balance between Tregs and Teffs, and may be an efficient therapeutic target for tumor and autoimmune diseases.
|
29623079 |
2018 |